Pfizer Inc. (PFE) said it has suspended the osteoarthritis clinical program for the investigational compound tanezumab, effective immediately, following a request by the FDA.
The worldwide suspension follows a small number of reports of tanezumab patients experiencing the worsening of osteoarthritis leading to joint replacement.
The clinical hold includes both the suspension of recruitment of new patients and the dosing of existing patients in the osteoarthritis program, as well as patients with osteoarthritis in other studies.
The FDA has asked the company to present its assessment of the potential implications of the adverse events in the osteoarthritis program for the other tanezumab clinical programs involving non-osteoporosis patients.
The company is actively working with the FDA, to determine the appropriate course of action, which will serve the best interest of patients.
For comments and feedback contact: editorial@rttnews.com
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.